Outcomes of venetoclax combined with homoharringtonine and cytarabine in fit adults patients with de novo adverse‐risk acute myeloid leukaemia: A single‐centre retrospective analysis

Abstract

AbstractAdverse‐risk acute myeloid leukemia (AML) has a dismal prognosis. We aimed to investigate the activity and tolerability of venetoclax combined with homoharringtonine (HHT) plus cytarabine (VHA) regimen for de novo adverse‐risk AML. Thirteen de novo AML patients with adverse‐risk factors were treated with venetoclax (100 mg day 1, 200 mg day 2, 400 mg days 3‐21), HHT (1 mg/m2 days 1‐5) and cytarabine (100 mg/m2 days 1‐5) (VHA regimen). Complete remission (CR) was achieved in 11/13 patient (84.6%), all of CR responders were measurable residual disease (MRD) negative detected by multi‐parameter flow cytometry (MFC). Grade 3‐4 neutropenia, anaemia, and thrombocytopenia occurred in most patients. Grade 3‐4 non haematological adverse events (AEs) included febrile neutropenia (4/13, 30.8%). With a median follow‐up of 10 months (range 4‐19), median overall survival and event‐free survival were not reached. VHA may be a promising and well‐tolerated regimen in de novo adverse‐risk AML.